Clinical trials: Drug-drug Interaction, open to volunteers
Herb-drug Interactions
Developing a Methodological Framework and a Dissemination Plan for Herb-drug Interactions-related Clinical Practice Guidelines
The goal of this observational study is to develop a methodological framework for clinical practice guidelines (CPGs) related to herb-drug interactions (HDIs).
- Trial name
- NCT07248826
- Testing
- Delphi method survey, Semi-structured interview
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Drug-drug Interaction
A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants
The study treatment BAY3389934 is under development for people with blood clotting problems that occur due to sepsis. Sepsis is a serious condition that happens when the body's reaction to an infection causes organ damage.
- Trial name
- NCT07652723
- Testing
- Aspirin, BAY3389934
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Pharmacogenomic Drug Interaction, Side Effect of Drug
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed…
- Conditions
- Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related
- Trial name
- PREPARE-Mayo (NCT06322238)
- Testing
- PGx panel test
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pharmacogenomic Drug Interaction
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
It is known that individuals respond differently to the same medicine with some people benefitting, some experiencing no effect and others suffering side-effects or even coming to harm.
- Trial name
- PHOENIX (NCT06907784)
- Testing
- Pharmacogenomic testing
- Where
- 5 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- NHS Greater Glasgow and Clyde
HIV Infections, Contraception
Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIV
This study is being done to understand how long-acting injectable cabotegravir (CAB-LA) used for HIV pre-exposure prophylaxis (PrEP) and hormonal contraceptive methods affect each other when used at the same time.
- Conditions
- HIV Infections, Contraception, Drug-drug Interaction, PrEP
- Trial name
- PHARAOH (NCT07516548)
- Testing
- Long-acting injectable cabotegravir (CAB-LA), No PrEP
- Where
- Botswana
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Lower Urinary Tract Symptoms, Intravenous Drug Usage
JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer
To identify the effects of JING SI HERBAL TEA in the treatment of lower urinary tract symptoms after intravesical therapy in patients with bladder cancer.
- Conditions
- Lower Urinary Tract Symptoms, Intravenous Drug Usage, Bladder Cancer, Herbal Interaction
- Trial name
- NCT05739071
- Testing
- JING SI HERBAL TEA
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Pharmacogenetics, Depression - Major Depressive Disorder
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment…
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Trial name
- COMPASS-PGx (NCT07373470)
- Testing
- Comprehensive medication management with PGx testing results, Usual Care
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Pittsburgh
Drug-drug Interactions
A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers
This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.
- Trial name
- DDI (NCT07784608)
- Testing
- Atorvastatin Calcium, Telmisartan
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants
This study adopts a single-center, open-label, same-subject sequential crossover clinical trial design, aiming to evaluate the effects of oral administration of rifampicin or itraconazole on the pharmacokinetic profiles of…
- Trial name
- NCT07809789
- Testing
- vorolanib and rifampicin, vorolanib and itraconazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants.
This study adopts a single-center, open-label, same-subject sequential crossover clinical trial design, aiming to evaluate the effects of oral administration of rifampicin or itraconazole on the pharmacokinetic profiles of…
- Trial name
- NCT07809815
- Testing
- Befotertinib and rifampicin, Befotertinib and itraconazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Diabete Type 2, Pharmacogenomic Drug Interaction
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
This research study aims to learn about how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron.
- Trial name
- PATHS-T2D (NCT07739537)
- Testing
- Orforglipron
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Drug-Drug Interaction
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
The main goal of this clinical study is to test how CYP2B6 genetic variations and efavirenz (cornerstone in HIV-1 therapy) dictate the disposition (PK) of CYP2B6 substrate (methadone) and PK and effect (PD) of CYP1A2 substrate…
- Trial name
- NCT05789173
- Testing
- Methadone and Tizanidine, Efavirenz, Methadone and Tizanidine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Drug Interaction Research
Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets
This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose…
- Trial name
- NCT07768111
- Testing
- 75mg Flonoltinib, 100mg Flonoltinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy Volunteers, Drug-Drug Interaction (DDI)
A Drug-Drug Interaction Study Between NTQ5082 Capsules and Midazolam Oral Solutio
This is a single-center, non-randomized, open-label, single-sequence, self-controlled drug-drug interaction study in healthy participants.
- Trial name
- NCT07745439
- Testing
- NTQ5082, Midazolam
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Contraception, Pharmacogenomic Drug Interaction
Oral Contraceptive Pill (OCP) Pharmacogenomics
The goal of this clinical trial is to evaluate how differences in specific parts of our DNA can influence how individual bodies break down the hormones contained within oral contraceptive pills, which could affect how well these…
- Trial name
- NCT06334315
- Testing
- Desogestrel / Ethinyl Estradiol Pill
- Where
- 2 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Yale University
Drug Interactions, Primary Prevention
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals.
- Conditions
- Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering
- Trial name
- SOLVE-LDL-C (NCT06865885)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Healthy Volunteer, Pharmacokinetics
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
This is a Phase 1, open-label, three-part, study in approximately 96 healthy adult participants between 18 and 55 years of age (both inclusive) (16 participants in Part 1, 20 participants in Part 2 and , and approximately 60…
- Conditions
- Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI)
- Trial name
- NCT06733675
- Testing
- Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Cancer (Solid Tumors), Interaction Drug Food
Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments…
- Trial name
- Dietary Supple (NCT07670234)
- Testing
- Dietary Supplement Use Assessment
- Where
- Morocco
- Volunteers
- 1,000 people
- Sponsor
- Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)